MCID: LYM049
MIFTS: 37

Lymphoma, Small Cleaved-Cell, Diffuse

Categories: Immune diseases

Aliases & Classifications for Lymphoma, Small Cleaved-Cell, Diffuse

MalaCards integrated aliases for Lymphoma, Small Cleaved-Cell, Diffuse:

Name: Lymphoma, Small Cleaved-Cell, Diffuse 38 76
Diffuse Small Cleaved Cell Lymphoma 55

Classifications:



Summaries for Lymphoma, Small Cleaved-Cell, Diffuse

MalaCards based summary : Lymphoma, Small Cleaved-Cell, Diffuse, also known as diffuse small cleaved cell lymphoma, is related to lymphoma and extramedullary plasmacytoma. An important gene associated with Lymphoma, Small Cleaved-Cell, Diffuse is BCL2 (BCL2, Apoptosis Regulator), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Small cleaved cells are a distinctive type of cell that appears in certain types of... more...

Related Diseases for Lymphoma, Small Cleaved-Cell, Diffuse

Graphical network of the top 20 diseases related to Lymphoma, Small Cleaved-Cell, Diffuse:



Diseases related to Lymphoma, Small Cleaved-Cell, Diffuse

Symptoms & Phenotypes for Lymphoma, Small Cleaved-Cell, Diffuse

GenomeRNAi Phenotypes related to Lymphoma, Small Cleaved-Cell, Diffuse according to GeneCards Suite gene sharing:

26 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.16 BCL2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.16 BCL2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.16 BCL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.16 CCND1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.16 CCND1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.16 BCL2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.16 CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.16 CCND1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.16 BCL2 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.16 BCL2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.16 BCL2 CCND1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.16 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.16 BCL2 CCND1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.16 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.16 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.16 BCL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.16 BCL2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.16 BCL2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.16 BCL2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.16 BCL2
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.8 BCL2 CCND1
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.8 BCL2
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 9.8 BCL2
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.8 BCL2
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.8 CCND1
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 9.8 CCND1
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.8 CCND1
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.8 CCND1
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.8 BCL2
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.8 BCL2
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.8 BCL2
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.8 BCL2
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.8 CCND1

Drugs & Therapeutics for Lymphoma, Small Cleaved-Cell, Diffuse

Drugs for Lymphoma, Small Cleaved-Cell, Diffuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 435)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
3
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
4 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
7 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
8 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
12
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
13
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
14 Orange Approved Phase 3
15
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
16
Ofloxacin Approved Phase 3 82419-36-1 4583
17
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
18
Idarubicin Approved Phase 3 58957-92-9 42890
19
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 55-98-1 2478
20
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
21
Bleomycin Approved, Investigational Phase 3,Phase 1,Phase 2 11056-06-7 5360373
22
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
23
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
24
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
25
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 57-22-7, 2068-78-2 5978
26
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
27
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
28
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
29
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
30
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
31
Etoposide Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
32
Mitoxantrone Approved, Investigational Phase 3,Phase 1,Phase 2 65271-80-9 4212
33
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
34
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
35
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
36
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
37
rituximab Approved Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 174722-31-7 10201696
38
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
39
Carboplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
40
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
41
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
43
Tazobactam Approved Phase 3 89786-04-9 123630
44
Vancomycin Approved Phase 3 1404-90-6 14969 441141
45
Piperacillin Approved Phase 3 66258-76-2 43672
46
Dalteparin Approved Phase 3 9005-49-6
47
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
48
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
49
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 51-75-2 4033
50
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2

Interventional clinical trials:

(show top 50) (show all 490)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
4 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
5 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
6 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
7 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
9 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
10 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
13 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
14 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
17 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
18 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
19 Combination Chemotherapy in Treating Patients With Lymphoma Completed NCT00002835 Phase 3 Carmustine;Cisplatin (CDDP);Cyclophosphamide;Cytarabine (ARA-C);Etoposide (VP-16);Idarubicin;Ifosfamide;Leucovorin Calcium;Melphalan;Methotrexate;Methylprednisolone;mitoxantrone hydrochloride (DHAD);Vincristine Sulfate
20 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
21 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
22 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
23 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
24 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
25 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
26 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
27 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
28 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
29 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
30 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
31 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
32 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
33 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
34 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
35 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
36 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
37 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
38 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
39 Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
40 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
41 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
42 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
43 Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation Terminated NCT00003056 Phase 3 cyclosporine;cyclosporine and methotrexate
44 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
45 Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma Unknown status NCT00006669 Phase 2 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
46 Beta Alethine in Treating Patients With Low-Grade Lymphoma Unknown status NCT00007839 Phase 1, Phase 2 beta alethine
47 Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00026429 Phase 2
48 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
49 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
50 Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00005959 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate

Search NIH Clinical Center for Lymphoma, Small Cleaved-Cell, Diffuse

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Small Cleaved-Cell, Diffuse cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lymphoma, Small Cleaved-Cell, Diffuse:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Lymphoma, Small Cleaved-Cell, Diffuse:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Lymphoma, Small Cleaved-Cell, Diffuse

Anatomical Context for Lymphoma, Small Cleaved-Cell, Diffuse

MalaCards organs/tissues related to Lymphoma, Small Cleaved-Cell, Diffuse:

41
Bone, Bone Marrow, B Cells, T Cells, Liver, Breast, Myeloid

Publications for Lymphoma, Small Cleaved-Cell, Diffuse

Articles related to Lymphoma, Small Cleaved-Cell, Diffuse:

# Title Authors Year
1
Histogenesis and pathogenesis of follicular small cleaved cell lymphoma (FSCCL), diffuse small cleaved cell lymphoma (DSCCL) and intermediate lymphocytic lymphoma/lymphocytic lymphoma of intermediate differentiation (ILL/IDL). ( 7642169 )
1994
2
The presence of bcl-1 and bcl-2 gene rearrangements in diffuse small cleaved-cell lymphoma. A disease with diverse molecular and immunophenotypic findings. ( 7981893 )
1994
3
Histogenesis of diffuse small cleaved cell lymphoma. An immunohistochemical and molecular genetic (bcl-2 gene) study with comparison to follicular small cleaved cell lymphoma and mantle zone lymphoma. ( 1643614 )
1992
4
Diffuse small cleaved-cell lymphoma: a heterogeneous disease with distinct immunobiologic subsets. ( 1634915 )
1992
5
Diffuse intermediate lymphocytic lymphoma. A clinicopathologic study and comparison with small lymphocytic lymphoma and diffuse small cleaved cell lymphoma. ( 2224798 )
1990
6
Intermediate lymphocytic lymphoma: an immunophenotypic study with comparison to small lymphocytic lymphoma and diffuse small cleaved cell lymphoma. ( 3286480 )
1988
7
Stage IIE diffuse small cleaved cell lymphoma of the cervix. ( 6674906 )
1983

Variations for Lymphoma, Small Cleaved-Cell, Diffuse

Expression for Lymphoma, Small Cleaved-Cell, Diffuse

Search GEO for disease gene expression data for Lymphoma, Small Cleaved-Cell, Diffuse.

Pathways for Lymphoma, Small Cleaved-Cell, Diffuse

Pathways related to Lymphoma, Small Cleaved-Cell, Diffuse according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.36 BCL2 CCND1
2 12.33 BCL2 CCND1
3
Show member pathways
12.28 BCL2 CCND1
4
Show member pathways
12.26 BCL2 CCND1
5
Show member pathways
12.2 BCL2 CCND1
6
Show member pathways
12.12 BCL2 CCND1
7 12.05 BCL2 CCND1
8
Show member pathways
12.01 BCL2 CCND1
9
Show member pathways
11.93 BCL2 CCND1
10
Show member pathways
11.91 BCL2 CCND1
11 11.83 BCL2 CCND1
12
Show member pathways
11.77 BCL2 CCND1
13
Show member pathways
11.73 BCL2 CCND1
14 11.67 BCL2 CCND1
15 11.66 BCL2 CCND1
16
Show member pathways
11.57 BCL2 CCND1
17 11.49 BCL2 CCND1
18 11.46 BCL2 CCND1
19 11.36 BCL2 CCND1
20 11.29 BCL2 CCND1
21 11.15 BCL2 CCND1
22 10.94 BCL2 CCND1
23 10.7 BCL2 CCND1
24 10.33 BCL2 CCND1

GO Terms for Lymphoma, Small Cleaved-Cell, Diffuse

Biological processes related to Lymphoma, Small Cleaved-Cell, Diffuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.46 BCL2 CCND1
2 cellular response to DNA damage stimulus GO:0006974 9.43 BCL2 CCND1
3 response to drug GO:0042493 9.4 BCL2 CCND1
4 cytokine-mediated signaling pathway GO:0019221 9.37 BCL2 CCND1
5 regulation of cell cycle GO:0051726 9.32 BCL2 CCND1
6 response to glucocorticoid GO:0051384 9.26 BCL2 CCND1
7 cellular response to organic substance GO:0071310 9.16 BCL2 CCND1
8 response to steroid hormone GO:0048545 8.96 BCL2 CCND1
9 response to iron ion GO:0010039 8.62 BCL2 CCND1

Molecular functions related to Lymphoma, Small Cleaved-Cell, Diffuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 8.62 BCL2 CCND1

Sources for Lymphoma, Small Cleaved-Cell, Diffuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....